Review Article
The Mystery of Exosomes in Gestational Diabetes Mellitus

Tong Chen and Dan Liu

Department of Endocrinology and Metabolism, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

Correspondence should be addressed to Dan Liu; liudandan303114@163.com

Received 13 October 2021; Accepted 31 May 2022; Published 8 June 2022

Academic Editor: Demetrios Kouretas

Copyright © 2022 Tong Chen and Dan Liu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gestational diabetes mellitus (GDM) is one of the common pregnancy complications, which increases the risk of short-term and long-term adverse consequences in both the mother and offspring. However, the pathophysiological mechanism of GDM is still poorly understood. Inflammation, insulin resistance and oxidative stress are considered critical factors in the occurrence and development of GDM. Although the lifestyle intervention and insulin are the primary treatment, adverse pregnancy outcomes still cannot be ignored. Exosomes have a specific function of carrying biological information, which can transmit information to target cells and play an essential role in intercellular communication. Their possible roles in normal pregnancy and GDM have been widely concerned. The possibility of exosomal cargos as biomarkers of GDM is proposed. This paper reviews the literature in recent years and discusses the role of exosomes in GDM and their possible mechanisms to provide some reference for the prediction, prevention, and treatment of GDM and improve the outcome of pregnancy.

1. Introduction

Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance that occurs for the first time during pregnancy and incidence of GDM in accordance with the increase in obesity and type 2 diabetes mellitus (T2DM) prevalence. GDM increases the incidence of perinatal complications such as macrosomia, cesarean section, preterm delivery, neonatal hypoglycemia, and hyperbilirubinemia and the maternal risk of T2DM and cardiovascular disease in the long term. The pathogenesis of GDM is complex and has not been fully clarified, which is believed to be related to insulin resistance, inflammation, oxidative stress, adipose tissue, and endothelial cell dysfunction [1, 2]. It is of great clinical value to further study the pathogenesis of GDM and put forward innovative prevention and treatment methods.

Extracellular vesicles (EVs) are nano-sized particles derived from the membrane, which play the role of intercellular communication. The exosome, also known as small extracellular vesicles (sEVs), is a subgroup concerned by many researchers [3, 4]. Exosomes are extracellular vesicles produced by various cells in the diameter of 50-150 nm, which are widely found in peripheral blood, urine, saliva, cerebrospinal fluid, and placenta. Exosomes carry cargos rich proteins, lipids, DNA, RNA, and other bioactive factors, which are released in the form of exocytosis to take a part in the process of intercellular information transmission, immune regulation, antigen presentation, tumor growth, and so on. At present, many studies have shown that exosomes are involved in the occurrence and development of a variety of diseases and may be used in the treatment of diseases. During pregnancy, all types of cells in the body secrete exosomes, including placenta, adipose tissue, liver, pancreas, and skeletal muscle [5]. Higher plasma concentrations of exosomes were observed in normal pregnant women than in nonpregnant women [6]. In addition, placental-derived exosomes were detected in maternal plasma as early as six weeks of gestation, and the concentration of exosomes gradually increased with gestation age [7]. The exosomes isolated from maternal blood have biological activity in vitro and can enter target cells through endocytosis [8]. Maternal sEVs can circulate from the mother to the fetus through the placental barrier, resulting in functional changes during pregnancy [9–11], indicating that sEVs play an important role in maintaining communication between the fetus and the mother.
2. Exosomes Derived from Different Tissue That Related with GDM

2.1. Placental-Derived Exosomes. As an important organ connecting mother and fetus, the placenta plays a crucial role in regulating maternal physiological function and nutritional exchange between mother and infant during pregnancy. Placental-derived exosomes are secreted by various placental cells during pregnancy, mainly syncytiotrophoblastic layer releasing a large amount of EVs through exocytosis [13, 14]. Placental-derived exosomes can be identified by human placental alkaline phosphatase (PLAP) because PLAP is a specific allosteric synthesized in the placenta [6, 15]. Compared with the control group, the particle size of exosomes in umbilical cord blood in the GDM group was larger and the concentration was higher [16]. It was well established that the concentration of placental-derived exosomes in patients with GDM was significantly higher than that in normal pregnant women [17], suggesting that maternal hyperglycemia can promote the release of placental exosomes into blood circulation. Furthermore, maternal hyperglycemia can also stimulate the biological activity of placental-derived exosomes [18]. Additionally, placental-derived EVs can regulate insulin sensitivity during normal pregnancy, while insulin signaling is weakened in placental-derived EVs of GDM [19].

2.2. Adipose Tissue-Derived Exosomes. Adipose tissue is mainly composed of adipocytes, whose function is to store fat. Exosomes have been isolated from the culture medium of adipose cells, adipose tissue, and adipose-derived stem cells [20, 21]. The amount of maternal fat increases during pregnancy, but adipose tissue hyperplasia and hypertrophy are associated with insulin resistance and abnormal metabolism [22]. It was reported that the adipose tissue of patients with GDM secreted more sEVs than normal pregnant women, and the increase in the number of sEVs was believed to be positively correlated with the Z score of birth weight of offspring [23], suggesting that a higher level of exosomes in adipose tissue may be involved in regulating fetal growth. However, this differs from Franzago et al. who found that the concentration of sEVs in adipocytes in the maternal circulation of GDM was lower than that in normal pregnancy [24]. Different conditions such as hypoxia and obesity can lead to changes in the composition of exosomes [25]. A total of 509 proteins were detected in exosomes derived from adipose tissue of obese and non-obese diabetic, of which 200 proteins were differentially expressed in exosomes of obese diabetes [25]. Obesity is a risk factor and potential mechanism of GDM [26]. Obesity during pregnancy can cause systemic inflammation. The increase of circulating proinflammatory cytokines in adipose tissue may result in the rise of placental inflammatory cytokines secreted by the placenta, thus changing the placental function, which may promote the occurrence of GDM [5]. Additionally, exosomes derived from adipose tissue in GDM are rich in proteins targeting key pathways, such as mitochondrial dysfunction, OXPHOS, and SIRT signaling pathways, and exosomes derived from adipose tissue of GDM have the ability to increase the expression of genes related to glycolysis and gluconeogenesis in placental cells [23], which also suggests that adipose tissue-derived sEVs may be associated with the pathogenesis of GDM.

3. The Possible Mechanism of Exosomes Participation in GDM

3.1. Regulation of Gene Expression through RNA. Exosomes contain many different types of RNA molecules, such as miRNA, circRNA, and lncRNA. These RNA molecules can act on receptor cells and exert biological functions such as intercellular signal transmission.

3.1.1. miRNA. miRNA is a wealthy class of small noncoding RNAs, which play a role in many biological processes by specifically binding to its target mRNA to induce its degradation or inhibit translation. More and more studies have found that some miRNAs involved in placental and fetal development are abnormally regulated in GDM, suggesting that miRNAs may be involved in the pathogenesis of GDM [8, 27]. The chromosome 19 miRNA cluster (C19MC), as an exosomes carrier, is expressed only in the placenta [28], the most important of which are miR-516b-5p, miR-517-5p, and miR-518a-3p [29]. Placental-derived miRNAs are released from syncytiotrophoblast cells into the maternal circulation [30, 31], and their expression levels are regulated by stimuli such as stress, circulating blood glucose and other pregnancy characteristics. The abundance of miR-518a-5p, miR-518b, miR-518c, miR-519e, miR-520c-3p, and miR-525-5p in placental exosomes of GDM patients was higher than that of the normal pregnancy group, and miR-520c-3p was related to placental oxygen supply [18]. However, the cellular targets of C19MC miRNAs have not been fully determined, which may include non-trophoblastic placental cells, maternal organs or fetal cells.

In addition, some non-C19MC-coded miRNAs, such as miR-16-5p and miR-222-3p, are also related to GDM [32]. miR-16-5p plays a regulatory role in PI3K/Akt, Wnt, insulin, and mTOR signaling pathways, and the overexpression of these signaling pathways is related to GDM [33, 34]. The gene encoding insulin receptor substrate proteins 1 and 2 (IRS1/IRS2) are the targets of miR-16-5p. The upregulation of miR-16-5p in GDM patients at the 2nd trimester will lead to the negative regulation of IRS1 and IRS2, which may lead to abnormal Wnt/β-catenin signaling and eventually lead to diabetes [35, 36]. The expression of miR-222-3p in serum of GDM patients was lower than that of control group either at the 17th or 26th week of pregnancy [37, 38]. Nevertheless, Shi et al. proved that miR-222-3p was upregulated in the adipose tissue of GDM [39]. Most of the genes involved in the pathways of insulin resistance are the targets of miR-16-5p and miR-222-3p [14, 40]. miR-103 and miR-107 are also closely related to insulin sensitivity [41]. Other studies...
reported that the levels of miR-132, miR-29a, and miR-222 in serum of patients with GDM decreased [37], while the levels of has-miR-16-5p, has-miR-17-5p, has-miR-19a-3p, has-miR-19b-3p, and has-miR-20a-5p in plasma of patients with GDM are increased [32]. The expressions of miRNA-125b and miRNA-144 were out of balance in the circulating exosomes and placenta of patients with GDM [42]. In summary, exosome-derived miRNAs are becoming a new participant in the development of GDM, which may become an attractive biomarker and potential therapeutic target.

3.1.2. circRNA. circRNA is a kind of endogenous noncoding RNA with wide distribution and diverse cellular functions. circRNAs can alter mRNA stability and inhibit protein activity by binding to RNA binding proteins [43]. circRNAs can also serve as templates for protein translation [44]. The enrichment and stability of circRNAs in exosomes have been discovered recently. circRNAs are involved in the development of GDM and fetal growth. A recent study shows that in patients with GDM, the expression of circ_0008285 was significantly upregulated, while that of circ_0001173 was decreased [45]. 88371 circRNAs in the umbilical cord blood exosomes of the two groups were evaluated, and the results showed that there was a differential expression of 507 circRNAs between GDM patients and control groups, of which 229 circRNAs were significantly upregulated in GDM patients and 278 circRNAs were downregulated considerably in GDM patients. Further circRNA/miRNA interaction analysis showed that most of the exosomal circRNAs contained miRNA binding sites and some of the miRNAs were related to GDM [46]. Exosomal circRNAs regulates gene expression through the miRNA sponge mechanism [47]. circRNAs have many miRNA binding sites that compete with miRNAs, so circRNAs may regulate gene expression by reducing the inhibition of miRNAs on target molecules. For example, miR-330, miR-23a, and miR-16-5p were upregulated in the plasma of patients with GDM [32, 48–50], and these miRNAs were paired with circ_0092108 downregulated in the exosomes of umbilical cord blood of patients with GDM. Therefore, the role of circRNAs in GDM may be related to the effect mediated by miRNAs. Nevertheless, the mechanism of circRNA-miRNA-target gene interaction needs to be further explored.

CircRNA polyribonucleotide nucleotidyltransferase 1 (Cir-PNPT1) is a newly discovered functional circRNA derived from the PNPT1 gene. It has been observed that it has different expression in GDM patients, which may be a risk factor for GDM [51]. Cir-PNPT1 was highly expressed in the placental tissues of GDM and high glucose (HG)-induced trophoblast cells. The expression of miR-889-3p decreased in GDM and HG-induced trophoblast cells, while the expression of PAK1 increased. Therefore, it is speculated that circ-PNPT1 may be involved in the inhibition of HG-induced trophoblast proliferation, migration, and invasion through the miR-889-3p/PAK1 axis [52]. Downregulation of circ-PNPT1 can alleviate trophoblast dysfuncion induced by HG, suggesting that silencing circ-PNPT1 may play a protective role in the progression of GDM [52], which puts forward a new insight into the pathogenesis of GDM. In summary, exosomal circ-PNPT1 may be an ideal biomarker for GDM treatment.

3.1.3. lncRNA. A study demonstrated that 84 mRNAs and 256 lncRNAs were differentially expressed in umbilical cord blood exosomes of patients with GDM compared with the control group. And further lncRNA/miRNA interaction analysis showed that most of the exosomal lncRNAs contained miRNA binding sites, some of which were related to GDM [16]. β-cell dysfunction is a pathophysiological characteristic of GDM. Some abnormal expressions of circulatory or placental-related lncRNAs are related to insulin resistance and β-cell dysfunction [53]. There is much evidence that exosomal lncRNAs can regulate miRNA-targeted gene expression, transcription, and protein synthesis [54, 55]. It has been reported that miR-362-5p and miR-508 were dysregulated in the placenta of patients with GDM [56]. miR-362-5p matched with Inc-ZNF800-1:1, which was confirmed to be downregulated in the umbilical cord blood exosomes of GDM, and miR-508 might combine with upregulated Inc-COX17-2:3. In consequence, exosomal lncRNAs may participate in GDM development and fetal growth through miRNA-mediated action. The potential mechanism of lncRNA-miRNA-target gene interaction in GDM is worthy of further studies. To sum up, exosomes play an essential role in GDM through RNA, especially miRNA. In Tables 1 and 2, we summarize the upregulated or downregulated expression levels of different types of RNA in GDM in recent years, all of which may be potential diagnostic and future targeted therapies for GDM.

3.2. Exosomes and Endothelial Cell Dysfunction. GDM mainly affects the function of placental vascular endothelial cells and then leads to the impairment of placental function. L-arginine/NO signaling pathway is one of the key signaling ways associated with vascular physiological changes and is associated with endothelial dysfunction. It was upregulated in GDM; that is, human cationic amino acid transporter 1 (hCAT-1) expression was increased, and eNOS activity and expression were increased [104–106]. Exosomes regulate the function of endothelial cells and are related to endothelial dysfunction [107, 108]. A few studies have shown that endothelial exosomes play a role as a regulator of L-arginine/NO signaling pathway, and endothelial exosomes participate in the regulation of fetal placental endothelial function in GDM by regulating PI3K/eNOS signaling pathway [109, 110]. A recent study has shown that exosomes from syncytiotrophoblast cells carry eNOS [111], which may lead to the production of NO. In addition, considering that exosomes in the fetal circulation of GDM may contain miRNA-203 that can induce NOS activity [112, 113], it may also affect the function of fetal endothelial cells. Exosomes released from human umbilical vein endothelial cells (HUVECs) were found to increase L-arginine transport through hCAT-1 [114, 115]. Interestingly, HUVECs from normal pregnant women blocked the increased L-arginine transport by GDM, the expression and activity of hCAT-1 and eNOS, and the activation of 44 and 42 kDa mitogen activated protein kinases (p44/p42mapk). Inhibition of p44/p42mapk
Table 1: The upregulated expression levels of RNAs in GDM and the possible mechanism involved in GDM.

| Sample                               | Upregulated                                      | Related mechanism                                                                 | Publication |
|--------------------------------------|--------------------------------------------------|-----------------------------------------------------------------------------------|-------------|
| Serum and urine                      | miR-429                                          | IRS-1: a target gene of miR-429                                                   | [57]        |
| Serum                                | miR-1323                                         | Inhibit trophoblast cell viability via inhibiting TP53INP1                         | [58]        |
| Serum                                | miR-16-5p, miR-29a-3p, and miR-134-5p             | —                                                                                 | [59]        |
| Placenta                             | miR-222                                          | Suppress inflammatory response by promoting CXCR4 and inactivating NLRP3 inflammasomes | [60]        |
| Serum                                | miR-2467                                         | Adiponectin: a target gene of miR-2467                                           | [61]        |
| Placenta                             | miR-140-3p                                       | Relate to defective placental IR signaling                                        | [62]        |
| Blood                                | miRNA-223                                        | —                                                                                 | [63]        |
| Serum                                | miR-195-5p                                       | Inhibit cell viability and proliferation and promote apoptosis by targeting EZH2   | [64]        |
| Blood                                | miR-330-3p                                       | INS-1 cell dysfunction                                                            | [65]        |
| Peripheral blood                     | miR-770-5p                                       | Influence pancreatic β-cell function                                              | [66]        |
| Placental macrophages                | miR-657                                          | Regulate macrophage proliferation, migration and polarization                      | [67]        |
| Serum                                | miRNA-19a and miRNA-19b                          | Influence inflammatory response via IL-37/NF-κB signaling axis                    | [68]        |
| Placenta-derived mononuclear macrophages | miR-657                                      | HG-induced VEC dysfunction                                                       | [69]        |
| Plasma                               | miR-137                                          | PAIP1: a miRNA-340 target gene                                                   | [70]        |
| Whole blood cells                    | miRNA-340                                        | Regulate pancreatic β-cell function by targeting the mTOR pathway                 | [71]        |
| Placenta tissue                      | miR-503                                          | Correlate with IR                                                                | [72]        |
| Plasma                               | miR-16-5p, miR-17-5p, and miR-20a-5p              | Link to the global DNA methylation by targeting Mecp2                           | [35]        |
| Placenta                             | miR-98                                           | Regulate the proliferation, migration and angiogenesis of HG-HUVECs via the miR-1200/MEOX2 axis | [73]        |
| HUVECs                               | circ_0074673                                     | circ_0074673 may maintain the HTR-8/SVneo trophoblast cell function by the PI3K/Akt signaling pathway | [74]        |
| Plasma                               | circ_0008285                                     | Promoted HG-induced trophoblast cell biological dysfunction through miR-889-3p/PAK1 axis | [45]        |
| Placental tissues                    | Circ-PNPT1                                       | RPL13P5 involved in insulin resistance via the PI3K-AKT and insulin signaling pathways | [52]        |
| Peripheral blood                     | ERMP1, TSPAN32, MRPL38, and RPL13P5              | Most of the exosomal lncRNAs harbored miRNA binding sites                         | [75]        |
| Umbilical cord blood exosomes        | Lnc-RXYLT1-3 : 2, Lnc-TFDP2-7 : 2, LncCOX17-2 : 3, and Lnc-ZBTB46-3 : 6 | Most of the exosomal lncRNAs harbored miRNA binding sites | [16]        |
| Plasma                               | MEG8                                             | —                                                                                 | [76]        |
| Placental tissues                    | MALAT1                                           | Associate with inflammation and the proliferation, invasion, and migration of placental trophoblastic cells via modulating the TGF-β/NF-κB signaling pathway | [77]        |
| Blood and placental villous tissues | MEG3                                             | miR-345-3p: a target; inhibit HTR-8/SVneo cell viability, and prevent cell migration and invasion in addition to inducing cell apoptosis | [78]        |
| Serum                                | MALAT1                                           | —                                                                                 | [79]        |
| Plasma                               | SOX20T                                          | —                                                                                 | [80]        |

Abbreviations: IRS: insulin receptor substrate; CXCR4: C-X-C chemokine receptor type 4; IR: insulin resistance; EZH2: enhancer of zeste homolog 2; IL: interleukin; NF-κB: nuclear factor κB; HG: high glucose; VEC: vascular endothelial cell; mTOR: mammalian target of rapamycin; Mecp2: methyl CpG binding protein 2; HUVECs: human umbilical vein endothelial cells; PI3K: phosphatidylinositol 3-kinase; Akt: protein kinase B; PAK1: p21 activated kinase 1; TGF-β: tumor growth factor β; MEG3: maternally expressed gene 3.
| Sample                          | Downregulated                  | Related mechanism                                                                 | Publication |
|--------------------------------|--------------------------------|-----------------------------------------------------------------------------------|-------------|
| Plasma                         | miR-574-5p and miR-3135b       | Associate with insulin signaling pathway                                           | [81]        |
| Placenta tissues               | miR-362-5p                     | Promote cell proliferation and inhibited apoptosis via targeting GSR and activating PI3K/Akt pathway | [82]        |
| Placenta                       | miR-30d                        | Affect trophoblast cell functions by targeting RAB8A                              | [83]        |
| Placenta and plasma            | miR-96-5p                      | Increased the viability of trophoblasts                                            | [84]        |
| Placenta-derived macrophages   | miR-6869-5p                    | Prevent from inflammation and inducing M2 macrophages                              | [85]        |
| Placenta villous               | miR-9 and miR-22               | Alter placental glucose metabolism by targeting GLUT1 and HK2                     | [86]        |
| Blood leukocytes               | miR-4646                       | —                                                                                 | [87]        |
| Placental tissue and peripheral blood | miR-345-3p                  | Inhibit HTR8-/SVneo cell apoptosis and promote cell proliferation and migration by targeting BAK1 | [88]        |
| Leukocytes                     | miR-155-5p                     | —                                                                                 | [89]        |
| Peripheral blood               | miR-193b                       | Inhibit autophagy and apoptosis by targeting IGFBP5                                | [90]        |
| Serum                          | miR-29a/b                      | —                                                                                 | [91]        |
| Serum and placenta             | miR-21                         | Inhibit cell growth and infiltration by upregulating PPAR-α                         | [92]        |
| Placenta                       | miR-29b                        | HIF3A: a direct target of miR-29b                                                 | [93]        |
| Serum and placenta             | miR-185                        | HOMA-IR ↓                                                                         | [94]        |
| Serum and placenta             | miR-132                        | Enhance the trophoblast cell proliferation                                         | [95]        |
| Placental of rats              | miRNA-221                      | Regulate proliferation, apoptosis and insulin secretion in islet β cells through targeting PAK1 | [96]        |
| Placenta tissues               | miR-96                         | Regulate PAK1 expression, insulin secretion, and β-cell function                   | [97]        |
| Blood                          | miR-494                        | Improve pancreatic β-cell dysfunction by targeting PTEN                           | [98]        |
| Plasma hsa_circRNA_102893      |                                | —                                                                                 | [99]        |
| Plasma circ_0001173            |                                | —                                                                                 | [45]        |
| Placenta and plasma            | hsa_circ_0005243               | Induce trophoblast cell dysfunction and inflammation by the β-catenin and NF-κB signal pathways | [100]       |
| Placenta circ_5824, circ_3636, and circ_0395 |                                | —                                                                                 | [101]       |
| Plasma SNHG17                  |                                | —                                                                                 | [102]       |
| Umbilical cord blood exosomes  | Lnc-TBC1D30-4:1, ENST00000596839.1, LncZNF800-1:1, Lnc-EIF4ENIF1-1:1, and Lnc-ATP8B3-3:1 | Most of the exosomal lincRNAs harbored miRNA binding sites                           | [16]        |
| Placenta                       | PVT1                           | Disrupt the function of trophoblast cells through PI3K/Akt pathway                  | [103]       |
| Blood leukocytes               | Pax8-AS1                       | —                                                                                 | [87]        |

Abbreviations: GSR: glutathione-disulfide reductase; PI3K: phosphatidylinositol 3-kinase; Akt: protein kinase B; BAK1: BCL2-antagonist/killer 1; IGFBP5: insulin-like growth factor-binding protein 5; HOMA: homeostasis model assessment; IR: insulin resistance; PAK1: p21-activated kinase 1; PTEN: phosphatase and tensin homolog; NF-κB: nuclear factor κB; Pax8-AS1: paired box 8 antisense 1.
could reverse the increase of L-arginine uptake by GDM. This is helpful to understand the mechanism of foetoplacental endothelial dysfunction in GDM [115]. The above studies suggest that exosomes from patients with GDM may play a potential role in fetal circulation and induce foetoplacental endothelial dysfunction.

3.3. Exosomes and Inflammation. GDM is associated with inflammation [116]. Placental-derived EVs of GDM have biological activity, releasing a large amount of tumor necrosis factor α (TNF-α), granulocyte macrophage colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ), IL-6 and IL-8 [17]. In addition, others studies also demonstrated that HG can trigger the release of EVs by trophoblast cells and placental EVs has biological activity, which in turn increase the release of proinflammatory cytokines such as GM-CSF, IL-6, IL-8, IL-10, and TNF-α from endothelial cells [5, 18] and promote the proinflammatory state of pregnant women with GDM.

3.4. Exosomes and Oxidative Stress. GDM is characterized by hyperglycemia. Under the condition of hyperglycemia, the body produces more reactive oxygen species (ROS), which leads to oxidative stress. It is suggested that in patients with GDM, hyperglycemia and oxidative stress may induce exosomes production, affect its transport in the fetal-placental vascular system, and contribute to endothelial dysfunction and activation [115]. Exosomes affect oxidative stress. Exosomes from different tissues have been shown to induce target cells to produce ROS. Exposure of normal pregnant HUVECs to HUVECs exosomes of GDM can induce GDM phenotype and increase eNOS total protein and synthesis of NO [115]. On the other hand, exosomes of HUVECs in normal pregnancy can also reverse the functional abnormalities of these cells induced by HG [117]. It is worth noting to mention that clinical trials of common antioxidants in patients with GDM have shown that this method is ineffective in reducing oxidative stress [118, 119]. Exosomes from HUVECs from normal pregnancy and GDM did not affect the production of ROS in GDM HUVECs [115], while in a previous study, GDM increased ROS production in primary HUVECs culture [120]. In addition, some studies have suggested that the increase in exosomes release may be an adaptive response of cells to oxidative stress [121, 122].

3.5. Exosomes and Insulin Resistance. Insulin resistance is involved in the development of GDM. Adipose tissue plays a major role in the development of insulin resistance during pregnancy [123, 124], and adipose tissue-derived exosomes have been shown to affect biological processes such as metabolism, inflammation, regulation of glucose homeostasis, and insulin sensitivity [125]. A study [23] analyzed and compared the protein expression of exosomes from adipose tissue. It was found that the differentially expressed proteins in adipose tissue of GDM were related to mitochondrial dysfunction and targeting SIRT, OXPHOS, and EIF2 signaling pathways, which may be involved in the pathophysiological process of GDM; mTOR, elf-4, and p70S6K were also found. This suggested that this exosomal protein may be involved in the pathophysiological process of GDM by regulating the maternal environment [23]. The normal function of mitochondria is critical to cell metabolism because it controls ATP production and disposal of reactive oxygen species through OXPHOS. In addition, mitochondria have been shown to be associated with insulin resistance [126]. SIRT enhances mitochondrial metabolism and plays a synergistic role by regulating mitochondrial gene expression and post-translational modifications of mitochondrial enzymes [127, 128]. Another study reported that the downregulation of SIRT in adipose tissue was associated with decreased insulin sensitivity [129]. The activation of placental mTOR signal promotes mitochondrial function, protein synthesis, and the transport of nutrients such as amino acids, thus increasing the utilization of fetal nutrients. Compared with exosomes derived from normal glucose tolerance, proteins targeting the mTOR signaling pathway are enriched in exosomes derived from GDM. Therefore, exosomes derived from GDM may regulate placental nutritional capacity by activating placental mTOR signal [23]. In addition, it has been suggested that insulin resistance in pregnant women with GDM and their newborns may be due to decreased signals of protein kinase B/Akt (Akt) and mammalian target of rapamycin (mTOR) in human placental endothelial cells [130]. In addition, exosomes-derived placental of patients with GDM carry a specific set of miRNAs associated with skeletal muscle insulin signal transduction and insulin resistance [19].

Two proteins related to the regulation of insulin sensitivity were identified. It was found that the expression of PAPP-A was downregulated and the expression of CaMK2β was upregulated in exosomes of patients with GDM [131]. PAPP-A is a glycoprotein mainly synthesized by villous and extravillous cytotrophoblasts [132]. The concentration of PAPP-A in maternal circulation increases throughout pregnancy and decreases after birth. Low concentrations of PAPP-A in maternal circulation are associated with adverse pregnancy outcomes, including GDM [133]. It is worth noting that PAPP-A levels in the first trimester of pregnancy are associated with insulin resistance later in pregnancy [133, 134]. The low expression of PAPP-A in exosomes may play an important role in the intercellular communication between placenta and maternal environment, which mediates the change of insulin sensitivity. CaMK2β regulates a range of processes, including metabolism and insulin sensitivity [135]. The role of CaMK2β in the pathophysiology of GDM needs to be further studied. Another study found that there were different protein expressions of spectrin alpha erythrocytic (SPTA)-1, CAMK2β, PAPP-A, periplin 4, fatty acid binding protein (FABP) 4, and hexokinase-3 in peripheral blood of patients with GDM compared with normal controls. Interestingly, these proteins have previously been shown to be expressed differently in insulin resistance [131].

4. Conclusions and Prospect

In recent years, interest has been emerging in the research of exosomes during pregnancy. Exosomes play a crucial role in normal physiological pregnancy, from exosomal loading to maternal-fetal interface communication in pathological
pregnancies such as GDM. A study found that visceral fat thickness in early pregnancy is more accurate in predicting GDM than BMI [136]. Another prospective study found that visceral fat thickness may predict GDM by regulating the miRNA-148 family of adipose-derived exosomes [137]. This suggests that the assessment of changes in exosomal content and composition may be the basis for the identification of potential diagnostic markers for GDM. In addition, further investigation of the mechanism of exosomes in normal pregnancy and GDM will increase our understanding of the function of circulating exosomes in patients with GDM and the pathophysiological mechanism of GDM, providing the basis for improving pregnancy outcome.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

[1] C. Nguyen-Ngo, N. Jayabalan, C. Salomon, and M. Lappas, “Molecular pathways disrupted by gestational diabetes mellitus,” Journal of Molecular Endocrinology, vol. 63, no. 3, pp. R51–R72, 2019.

[2] J. F. Flows, J. L. Stanley, P. N. Baker, C. M. Reynolds, and M. H. Vickers, “The pathophysiology of gestational diabetes mellitus,” International Journal of Molecular Sciences, vol. 19, no. 11, article 3342, 2018.

[3] Y. Zhang, J. Bi, J. Huang, S. Du, and P. Li, “Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications,” International Journal of Nanomedicine, vol. Volume 15, pp. 6917–6934, 2020.

[4] R. Kalluri and V. S. LeBlue, “The biology, function, and biomedical applications of exosomes,” Science, vol. 367, no. 6478, article eaau6977, 2020.

[5] N. Jayabalan, S. Nair, Z. Nuzhat et al., “Cross talk between adipose tissue and placenta in obese and gestational diabetes mellitus pregnancies via exosomes,” Frontiers in Endocrinology, vol. 8, p. 239, 2017.

[6] C. Salomon, M. J. Torres, M. Kobayashi et al., “A gestational profile of placental exosomes in maternal plasma and their effects on endothelial cell migration,” PLoS One, vol. 9, no. 6, article e98667, 2014.

[7] G. Zhao, C. Yang, J. Yang et al., “Placental exosome-mediated Bta-miR-499-Lin28B/let-7 axis regulates inflammatory bias during early pregnancy,” Cell Death & Disease, vol. 9, no. 6, pp. 1–18, 2018.

[8] M. D. Mitchell, H. N. Peiris, M. Kobayashi et al., “Placental exosomes in normal and complicated pregnancy,” American Journal of Obstetrics and Gynecology, vol. 213, no. 4, pp. S173–S181, 2015.

[9] G. Chang, J. F. Mouillet, T. Mishima et al., “Expression and trafficking of placental microRNAs at the feto-maternal interface,” The FASEB Journal, vol. 31, no. 7, pp. 2760–2770, 2017.

[10] S. Sheller-Miller, K. Choi, C. Choi, and R. Menon, “Cyclical recombinase-reporter mouse model to determine exosome communication and function during pregnancy,” American Journal of Obstetrics and Gynecology, vol. 221, no. 5, pp. 502.e1–502.e12, 2019.

[11] R. Shi, L. Zhao, W. Cai et al., “Maternal exosomes in diabetes contribute to the cardiac development deficiency,” Biochemical and Biophysical Research Communications, vol. 483, no. 1, pp. 602–608, 2017.

[12] J. F. Floriano, G. Willis, F. Catapano et al., “Exosomes could offer new options to combat the long-term complications inflicted by gestational diabetes mellitus,” Cell, vol. 9, no. 3, article 675, 2020.

[13] S. Sarker, K. Scholz-Romerio, A. Perez et al., “Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy,” Journal of Translational Medicine, vol. 12, pp. 1–19, 2014.

[14] E. Guarino, C. Delli Poggi, G. E. Gricco et al., “Circulating microRNAs as biomarkers of gestational diabetes mellitus: updates and perspectives,” The Journal of Endocrinology, vol. 2018, pp. 1–11, 2018.

[15] A. Sabapatha, C. Gercel-Taylor, and D. D. Taylor, “Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences,” American Journal of Reproductive Immunology, vol. 56, no. 5–6, pp. 345–355, 2006.

[16] M. Cao, L. Zhang, Y. Lin et al., “Differential mRNA and long noncoding RNA expression profiles in umbilical cord blood exosomes from gestational diabetes mellitus patients,” DNA and Cell Biology, vol. 39, no. 11, pp. 2005–2016, 2020.

[17] C. Salomon, K. Scholz-Romerio, S. Sarker et al., “Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation,” Diabetes, vol. 65, no. 3, pp. 598–609, 2016.

[18] G. E. Rice, K. Scholz-Romerio, E. Sweeney et al., “The effect of glucose on the release and bioactivity of exosomes from first trimester trophoblast cells,” The Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 10, pp. E1280–E1288, 2015.

[19] S. Nair, N. Jayabalan, D. Guanzon et al., “Human placental exosomes in gestational diabetes mellitus carry a specific set of miRNAs associated with skeletal muscle insulin sensitivity,” Clinical Science (London, England), vol. 132, no. 22, pp. 2451–2467, 2018.

[20] Z. B. Deng, A. Poliakov, R. W. Hardy et al., “Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance,” Diabetes, vol. 58, no. 11, pp. 2498–2505, 2009.

[21] R. Ogawa, C. Tanaka, M. Sato et al., “Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation,” Biochemical and Biophysical Research Communications, vol. 398, no. 4, pp. 723–729, 2010.

[22] J. I. Kim, J. Y. Huh, J. H. Sohn et al., “Lipid-overloaded enlarged adipocytes provoke insulin resistance independent of inflammation,” Molecular and Cellular Biology, vol. 35, no. 10, pp. 1686–1699, 2015.

[23] N. Jayabalan, A. Lai, V. Ormazabal et al., “Adipose tissue exosomal proteomic profile reveals a role on placenta glucose metabolism in gestational diabetes mellitus,” The Journal of Clinical Endocrinology and Metabolism, vol. 104, no. 5, pp. 1735–1752, 2019.

[24] M. Franzago, P. Lanuti, F. Fraticelli et al., “Biological insight into the extracellular vesicles in women with and without gestational diabetes,” Journal of Endocrinological Investigation, vol. 44, no. 1, pp. 49–61, 2021.
[25] J. E. Lee, P. G. Moon, I. K. Lee, and M. C. Baek, "Proteomic analysis of extracellular vesicles released by adipocytes of Otsuka Long-Evans Tokushima Fatty (OLETF) rats," The Protein Journal, vol. 34, no. 3, pp. 220–235, 2015.

[26] M. Lewandowska, B. Węckowska, and S. Sajdak, "Pre-pregnancy obesity, excessive gestational weight gain, and the risk of pregnancy-induced hypertension and gestational diabetes mellitus," Journal of Clinical Medicine, vol. 9, no. 6, article 1980, 2020.

[27] G. Rahimi, N. Jafari, M. Khodabakhsh, Z. Shirzad, and H. P. Dogah, "Upregulation of microRNA processing enzymes Drosha and Dicer in gestational diabetes mellitus," Gynecological Endocrinology, vol. 31, no. 2, pp. 156–159, 2015.

[28] R. B. Donker, J. F. Mouillet, T. Chu et al., "The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes," Molecular Human Reproduction, vol. 18, no. 8, pp. 417–424, 2012.

[29] S. S. Luo, O. Ishibashi, G. Ishikawa et al., "Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes," Biology of Reproduction, vol. 81, no. 4, pp. 717–729, 2009.

[30] S. S. Chim, T. K. Shing, E. C. Hung et al., "Detection and characterization of placental microRNAs in maternal plasma," Clinical Chemistry, vol. 54, no. 3, pp. 482–490, 2008.

[31] Y. Zhu, F. Tian, H. Li, Y. Zhou, J. Lu, and Q. Ge, "Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus," International Journal of Gynaecology and Obstetrics, vol. 130, no. 1, pp. 49–53, 2015.

[32] H. V. Oostdam, A. Sofia, J. C. Torro Ortiz et al., "Placental exosomes isolated from urine of patients with gestational diabetes exhibit a differential profile expression of microRNAs across gestation," International Journal of Molecular Medicine, vol. 46, no. 2, pp. 546–560, 2020.

[33] D. N. Kwon, B. S. Chang, and J. H. Kim, "MicroRNA dysregulation in liver and pancreas of CMP-Neu5Ac hydroxylase null mice disrupts insulin/PI3K-AKT signaling," BioMed Research International, vol. 2014, Article ID 236385, 12 pages, 2014.

[34] Y. L. Cao, Y. J. Jia, B. H. Xing, D. D. Shi, and X. J. Dong, "Plasma microRNA-16-5p, -17-5p and -20a-5p: novel diagnostic biomarkers for gestational diabetes mellitus," The Journal of Obstetrics and Gynaecology Research, vol. 43, no. 6, pp. 974–981, 2017.

[35] Y. Geng, Y. Ju, F. Ren et al., "Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/β-catenin signaling through blocking autophagic degradation of dishevelled2," The Journal of Biological Chemistry, vol. 289, no. 16, pp. 11230–11241, 2014.

[36] C. Zhao, J. Dong, T. Jiang et al., "Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus," PLoS One, vol. 6, no. 8, article e23925, 2011.

[37] C. Pfeiffer, S. Dias, P. Rheeder, and S. Adam, "Decreased expression of circulating miR-20a-5p in South African women with gestational diabetes mellitus," Molecular Diagnosis & Therapy, vol. 22, no. 3, pp. 345–352, 2018.

[38] Z. Shi, C. Zhao, X. Guo et al., "Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance," Endocrinology, vol. 155, no. 5, pp. 1982–1990, 2014.

[39] M. Trajkovski, J. Hausser, J. Soutschek et al., "MicroRNAs 103 and 107 regulate insulin sensitivity," Nature, vol. 474, no. 7353, pp. 649–653, 2011.

[40] J. S. M. Cuff, O. Holland, C. Salomon, G. E. Rice, and A. V. Perkins, "Review: placental derived biomarkers of pregnancy disorders," Placenta, vol. 54, pp. 104–110, 2017.

[41] J. E. Lee, P. G. Moon, I. K. Lee, and M. C. Baek, "Proteomic analysis of extracellular vesicles released by adipocytes of Otsuka Long-Evans Tokushima Fatty (OLETF) rats," The Protein Journal, vol. 34, no. 3, pp. 220–235, 2015.

[42] M. Lewandowska, B. Węckowska, and S. Sajdak, "Pre-pregnancy obesity, excessive gestational weight gain, and the risk of pregnancy-induced hypertension and gestational diabetes mellitus," Journal of Clinical Medicine, vol. 9, no. 6, article 1980, 2020.

[43] G. Rahimi, N. Jafari, M. Khodabakhsh, Z. Shirzad, and H. P. Dogah, "Upregulation of microRNA processing enzymes Drosha and Dicer in gestational diabetes mellitus," Gynecological Endocrinology, vol. 31, no. 2, pp. 156–159, 2015.

[44] R. B. Donker, J. F. Mouillet, T. Chu et al., "The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes," Molecular Human Reproduction, vol. 18, no. 8, pp. 417–424, 2012.

[45] S. S. Luo, O. Iishibashi, G. Ishikawa et al., "Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes," Biology of Reproduction, vol. 81, no. 4, pp. 717–729, 2009.

[46] S. S. Chim, T. K. Shing, E. C. Hung et al., "Detection and characterization of placental microRNAs in maternal plasma," Clinical Chemistry, vol. 54, no. 3, pp. 482–490, 2008.

[47] Y. Zhu, F. Tian, H. Li, Y. Zhou, J. Lu, and Q. Ge, "Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus," International Journal of Gynaecology and Obstetrics, vol. 130, no. 1, pp. 49–53, 2015.

[48] H. V. Oostdam, A. Sofia, J. C. Torro Ortiz et al., "Placental exosomes isolated from urine of patients with gestational diabetes exhibit a differential profile expression of microRNAs across gestation," International Journal of Molecular Medicine, vol. 46, no. 2, pp. 546–560, 2020.

[49] D. N. Kwon, B. S. Chang, and J. H. Kim, "MicroRNA dysregulation in liver and pancreas of CMP-Neu5Ac hydroxylase null mice disrupts insulin/PI3K-AKT signaling," BioMed Research International, vol. 2014, Article ID 236385, 12 pages, 2014.

[50] Y. L. Cao, Y. J. Jia, B. H. Xing, D. D. Shi, and X. J. Dong, "Plasma microRNA-16-5p, -17-5p and -20a-5p: novel diagnostic biomarkers for gestational diabetes mellitus," The Journal of Obstetrics and Gynaecology Research, vol. 43, no. 6, pp. 974–981, 2017.

[51] Y. Geng, Y. Ju, F. Ren et al., "Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/β-catenin signaling through blocking autophagic degradation of dishevelled2," The Journal of Biological Chemistry, vol. 289, no. 16, pp. 11230–11241, 2014.

[52] C. Zhao, J. Dong, T. Jiang et al., "Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus," PLoS One, vol. 6, no. 8, article e23925, 2011.

[53] C. Pfeiffer, S. Dias, P. Rheeder, and S. Adam, "Decreased expression of circulating miR-20a-5p in South African women with gestational diabetes mellitus," Molecular Diagnosis & Therapy, vol. 22, no. 3, pp. 345–352, 2018.

[54] Z. Shi, C. Zhao, X. Guo et al., "Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance," Endocrinology, vol. 155, no. 5, pp. 1982–1990, 2014.

[55] M. Trajkovski, J. Hausser, J. Soutschek et al., "MicroRNAs 103 and 107 regulate insulin sensitivity," Nature, vol. 474, no. 7353, pp. 649–653, 2011.
Y. L. Zhang and X. Q. Chen, "Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression," Molecular Cancer, vol. 17, no. 1, pp. 1–13, 2018.

J. Li, L. Song, L. Zhou et al., "A MicroRNA signature in gestational diabetes mellitus associated with risk of macrosomia," Cellular Physiology and Biochemistry, vol. 37, no. 1, pp. 243–252, 2015.

L. Wei, C. Cao, X. Ma, X. Wang, M. Wang, and P. Zhang, “Elevated serum and urine MiR-429 contributes to the progression of gestational diabetes mellitus,” Clinical Laboratory, vol. 67, no. 5, 2021.

L. Liu, J. Zhang, and Y. Liu, "MicroRNA-1323 serves as a biomarker in gestational diabetes mellitus and aggravates high glucose-induced inhibition of trophoblast cell viability by suppressing TP53INP1," Experimental and Therapeutic Medicine, vol. 21, no. 3, p. 230, 2021.

A. E. Serensen, M. N. M. van Poppel, G. Desoye et al., “The predictive value of miR-16, -29a and -134 for early identification of gestational diabetes: a nested analysis of the DALI cohort,” Cell, vol. 10, no. 1, p. 170, 2021.

H. Zhang, S. Luan, X. Xiao, L. Lin, X. Zhao, and X. Liu, “Silenced microRNA-222 suppresses inflammatory response in gestational diabetes mellitus mice by promoting CXCR4,” Life Sciences, vol. 266, article 118850, 2021.

S. Dai, X. Zhu, and H. Xia, "MiR-2467 is a potential marker for prediction of gestational diabetes mellitus in pregnancy," Clinical Laboratory, vol. 66, no. 10/2020, 2020.

C. Zhao, C. Zhao, and H. Zhao, "Defective insulin receptor signaling in patients with gestational diabetes is related to dysregulated miR-140 which can be improved by naringenin," The International Journal of Biochemistry & Cell Biology, vol. 128, article 105824, 2020.

A. Abdeltawab, M. E. Zaki, Y. Abdeldayem, A. A. Mohamed, and S. M. Zaid, “Circulating micro RNA-223 and angiopoietin-like protein 8 as biomarkers of gestational diabetes mellitus,” British Journal of Biomedical Science, vol. 78, no. 1, pp. 12–17, 2021.

J. Wang, Y. Pan, F. Dai, F. Wang, H. Qiu, and X. Huang, "Serum miR-195-5p is upregulated in gestational diabetes mellitus," Journal of Clinical Laboratory Analysis, vol. 34, no. 8, article e233255, 2020.

Y. Xiao, J. Ding, Y. Shi et al., “MiR-330-3p contributes to INS-1 cell dysfunction by targeting glucokinase in gestational diabetes mellitus,” The Journal of Obstetrics and Gynaecology Research, vol. 46, no. 6, pp. 866–875, 2020.

Y. L. Zhang and X. Q. Chen, "Dysregulation of microRNA-770-5p influences pancreatic-β-cell function by targeting TP53 regulated inhibitor of apoptosis 1 in gestational diabetes mellitus," European Review for Medical and Pharmacological Sciences, vol. 24, no. 2, pp. 793–801, 2020.

P. Wang, Z. Wang, G. Liu et al., "miR-657 promotes macrophage polarization toward M1 by targeting FAM46C in gestational diabetes mellitus," Mediators of Inflammation, vol. 2019, Article ID 4851214, 9 pages, 2019.

F. Wang, X. Zhang, and H. Zhou, "Role of cell free microRNA-19a and microRNA-19b in gestational diabetes mellitus patients," J Biotech, vol. 9, no. 11, pp. 1–5, 2019.

P. Wang, H. Wang, C. Li et al., “Dysregulation of microRNA-657 influences inflammatory response via targeting interleukin-37 in gestational diabetes mellitus,” Journal of Cellular Physiology, vol. 234, no. 5, pp. 7141–7148, 2019.
PTPRO in gestational diabetes mellitus,” *Mediators of Inflammation*, vol. 2021, Article ID 6966636, 8 pages, 2021.

[86] T. R. Song, G. D. Su, Y. L. Chi, T. Wu, Y. Xu, and C. C. Chen, “Dysregulated miRNAs contribute to altered placental glucose metabolism in patients with gestational diabetes via targeting GLUT1 and HK2,” *Placenta*, vol. 105, pp. 14–22, 2021.

[87] J. Hu, H. Mu, L. Gao et al., “Diagnostic value of candidate noncoding RNAs in leukocytes of patients with gestational diabetes mellitus,” *Experimental and Therapeutic Medicine*, vol. 21, no. 2, p. 145, 2021.

[88] Y. Li and J. Zhuang, “miR-345-3p serves a protective role during gestational diabetes mellitus by targeting BAK1,” *Experimental and Therapeutic Medicine*, vol. 21, no. 1, pp. 1–1, 2021.

[89] M. Hocaoglu, S. Demirer, I. Loclar Karaalp et al., “Identification of miR-16-5p and miR-155-5p microRNAs differentially expressed in circulating leukocytes of pregnant women with polycystic ovary syndrome and gestational diabetes,” *Gynecological Endocrinology*, vol. 37, no. 3, pp. 216–220, 2021.

[90] Y. Ji, W. Zhang, J. Yang, and C. Li, “MiR-193b inhibits autophagy and apoptosis by targeting IGFBP5 in high glucose-induced trophoblasts,” *Placenta*, vol. 101, pp. 185–193, 2020.

[91] L. Deng, Y. Huang, L. Li, H. Chen, and J. Su, “Serum miR-29a/b expression in gestational diabetes mellitus and its influence on prognosis evaluation,” *The Journal of International Medical Research*, vol. 48, no. 9, article 300060520954763, 2020.

[92] C. Y. Guan, S. Tian, J. L. Cao, X. Q. Wang, X. Ma, and H. F. Xia, “Down-regulated miR-21 in gestational diabetes mellitus placenta induces PPAR-α to inhibit cell proliferation and infiltration,” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 13, pp. 3009–3034, 2020.

[93] D. G. Sun, S. Tian, L. Zhang et al., “The miRNA-29b is downregulated in placenta during gestational diabetes mellitus and may alter placenta development by regulating trophoblast migration and invasion through a HIF3A-dependent mechanism,” *Frontiers in Endocrinology*, vol. 11, article 169, 2020.

[94] S. Qi and X. Wang, “Decreased expression of miR-185 in serum and placenta of patients with gestational diabetes mellitus,” *Clinical Laboratory*, vol. 65, no. 12, 2019.

[95] X. Zhou, C. Xiang, and X. Zheng, “miR-132 serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell viability,” *Diagnostic Pathology*, vol. 14, no. 1, pp. 1–7, 2019.

[96] H. Zhao and S. Tao, “miRNA-221 protects islet β cell function in gestational diabetes mellitus by targeting PAK1,” *Biochemical and Biophysical Research Communications*, vol. 520, no. 1, pp. 218–224, 2019.

[97] L. Li, S. Wang, H. Li et al., “microRNA-96 protects pancreatic β-cell function by targeting PAK1 in gestational diabetes mellitus,” *BioFactors*, vol. 44, no. 6, pp. 539–547, 2018.

[98] Y. He, J. Bai, P. Liu et al., “miR–494 protects pancreatic β-cell function by targeting PTEN in gestational diabetes mellitus,” *EXCLI Journal*, vol. 16, pp. 1297–1307, 2017.

[99] S. Poolla-Kella, R. A. Steinman, B. Mesmar, and R. Malek, “ Gestational diabetes mellitus: post-partum risk and follow up,” *Reviews on Recent Clinical Trials*, vol. 13, no. 1, pp. 5–14, 2018.

[100] H. Wang, W. Zhou, G. She, B. Yu, and L. Sun, “Downregulation of hsa_circ_0005243 induces trophoblast cell dysfunction and inflammation via the β-catenin and NF-κB pathways,” *Reproductive Biology and Endocrinology*, vol. 18, no. 1, article 51, 2020.

[101] H. Wang, G. She, W. Zhou, K. Liu, J. Miao, and B. Yu, “Expression profile of circular RNAs in placentas of women with gestational diabetes mellitus,” *Endocrine Journal*, vol. 66, no. 5, pp. 431–441, 2019.

[102] J. Li, B. Du, X. Geng, and L. Zhou, “IncRNA SNHG17 is downregulated in gestational diabetes mellitus (GDM) and has predictive values,” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 14, pp. 831–838, 2021.

[103] Q. Wang, X. Lu, C. Li et al., “Down-regulated long non-coding RNA PVT1 contributes to gestational diabetes mellitus and preeclampsia via regulation of human trophoblast cells,” *Biomedicine & Pharmacotherapy*, vol. 120, article 109501, 2019.

[104] E. Guzmán-Gutiérrez, A. Armella, F. Toledo, F. Pardo, A. Leiva, and L. Sobrevia, “Insulin requires A1 adenosine receptors expression to reverse gestational diabetes-increased L-arginine transport in human umbilical vein endothelium,” *Purinergic Signal*, vol. 12, no. 1, pp. 175–190, 2016.

[105] R. San Martin and L. Sobrevia, “Gestational diabetes and the adenosine/L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium,” *Placenta*, vol. 27, no. 1, pp. 1–1, 2006.

[106] F. Westermeier, C. Puebla, J. L. Vega et al., “Equilibrative nucleoside transporters in fetal endothelial dysfunction in diabetes mellitus and hyperglycaemia,” *Current Vascular Pharmacology*, vol. 7, no. 4, pp. 435–449, 2009.

[107] X. Li, C. Chen, L. Wei et al., “Exosomes derived from endothelial progenitor cells attenuate vascular repair and accelerate reendothelialization by enhancing endothelial function,” *Cytotherapy*, vol. 18, no. 2, pp. 253–262, 2016.

[108] A. Khalyfa, C. Zhang, A. A. Khalyfa et al., “Effect on intermittent hypoxia on plasma exosomal micro RNA signature and endothelial function in healthy adults,” *Sleep*, vol. 39, no. 12, pp. 2077–2090, 2016.

[109] R. Ju, Z. W. Zhuang, J. Zhang et al., “Angiopoietin-2 secretion by endothelial cell exosomes: regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways,” *The Journal of Biological Chemistry*, vol. 289, no. 1, pp. 510–519, 2014.

[110] F. Westermeier, C. Salomón, M. Farias et al., “Insulin requires normal expression and signaling of insulin receptor a to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium,” *The FASEB Journal*, vol. 29, no. 1, pp. 37–49, 2015.

[111] C. Motta-Mejía, N. Kandzija, W. Zhang et al., “Placental vesicles carry active endothelial nitric oxide synthase and their activity is reduced in preeclampsia,” *Hypertension*, vol. 70, no. 2, pp. 372–381, 2017.

[112] F. Pan, J. Xu, Q. Zhang et al., “Identification and characterization of the MicroRNA profile in aging rats with erectile dysfunction,” *The Journal of Sexual Medicine*, vol. 11, no. 7, pp. 1646–1656, 2014.

[113] G. Wu, G. Yang, R. Zhang et al., “Altered microRNA expression profiles of extracellular vesicles in nasal mucus from patients with allergic rhinitis,” *Allergy, Asthma & Immunology Research*, vol. 7, no. 5, pp. 449–457, 2015.
[114] O. G. de Jong, M. C. Verhaar, Y. Chen et al., “Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes,” *Journal of Extracellular Vesicles*, vol. 1, no. 1, 2012.

[115] T. Sáez, R. Salsoso, A. Leiva et al., “Human umbilical vein endothelium-derived exosomes play a role in foetalplacental endothelial dysfunction in gestational diabetes mellitus,” *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1864, no. 2, pp. 499–508, 2018.

[116] A. C. Richardson and M. W. Carpenter, “Inflammatory mediators in gestational diabetes mellitus,” *Obstetrics and Gynecology Clinics of North America*, vol. 34, no. 2, pp. 213–224, 2007.

[117] T. Sáez, P. de Vos, J. Kuipers, L. Sobrevia, and M. M. Faas, “Fetoplacental endothelial exosomes modulate high d-glucose-induced endothelial dysfunction,” *Placenta*, vol. 66, pp. 26–35, 2018.

[118] H. A. Anaya, F. X. Yi, D. S. Boeldt et al., “Changes in Ca2+ signaling and nitric oxide output by human umbilical vein endothelium in diabetic and gestational diabetic pregnancies,” *Biology of Reproduction*, vol. 93, no. 3, article 60, 2015.

[119] A. S. De Vriese, T. J. Verbeuren, J. Van de Voorde, N. H. Lameire, and P. M. Vanhoutte, “Endothelial dysfunction in diabetes,” *British Journal of Pharmacology*, vol. 130, no. 5, pp. 963–974, 2000.

[120] S. A. Sultan, W. Liu, Y. Peng, W. Roberts, D. Whitelaw, and A. M. Graham, “The role of maternal gestational diabetes in inducing fetal endothelial dysfunction,” *Journal of Cellular Physiology*, vol. 230, no. 11, pp. 2695–2705, 2015.

[121] Y. Bai, Y. D. Han, X. L. Yan et al., “Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury,” *Biochemical and Biophysical Research Communications*, vol. 500, no. 2, pp. 310–317, 2018.

[122] M. Hedlund, O. Nagaeva, D. Kargl, V. Baranov, and L. Mincheva-Nilsson, “Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells,” *PLoS One*, vol. 6, no. 2, article e16899, 2011.

[123] R. Rojas-Rodriguez, L. M. Lifshitz, K. D. Bellve et al., “Human adipose tissue expansion in pregnancy is impaired in gestational diabetes mellitus,” *Diabetologia*, vol. 58, no. 9, pp. 2106–2115, 2015.

[124] M. Lappas, “Effect of pre-existing maternal obesity, gestational diabetes and adipokines on the expression of genes involved in lipid metabolism in adipose tissue,” *Metabolism*, vol. 63, no. 2, pp. 250–262, 2014.

[125] C. Nguyen-Ngo, N. Jayabalain, P. Haghvirdizadeh, C. Salomon, and M. Lappas, “Role of adipose tissue in regulating fetal growth in gestational diabetes mellitus,” *Placenta*, vol. 102, pp. 39–48, 2020.

[126] C. H. Wang, C. C. Wang, H. C. Huang, and Y. H. Wei, “Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes,” *The FEBS Journal*, vol. 280, no. 4, pp. 1039–1050, 2013.

[127] A. P. Gomes, N. L. Price, A. J. Ling et al., “Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging,” *Cell*, vol. 155, no. 7, pp. 1624–1638, 2013.

[128] P. Parihar, I. Solanki, M. L. Mansuri, and M. S. Parihar, “Mitochondrial sirtuins: emerging roles in metabolic regulations, energy homeostasis and diseases,” *Experimental Gerontology*, vol. 61, pp. 130–141, 2015.

[129] M. Stefanowicz, A. Nikolajuk, N. Matulewicz, and M. Karczewska-Kupczewska, “Adipose tissue, but not skeletal muscle, sirtuin 1 expression is decreased in obesity and related to insulin sensitivity,” *Endocrine*, vol. 60, no. 2, pp. 263–271, 2018.

[130] R. Villalobos-Labra, L. Silva, M. Subibra et al., “Akt/mTOR role in human foetalplacental vascular insulin resistance in diseases of pregnancy,” *Journal Diabetes Research*, vol. 2017, article 5947859, 13 pages, 2017.

[131] N. Jayabalain, A. Dai, S. Nair et al., “Quantitative proteomics by SWATH-MS suggest an association between circulating exosomes and maternal metabolic changes in gestational diabetes mellitus,” *Proteomics*, vol. 19, no. 1-2, article e1800164, 2019.

[132] J. Guibourdenche, J. L. Frendo, G. Pidoux et al., “Expression of pregnancy-associated plasma protein-a (PAPP-A) during human villous trophoblast differentiation in vitro,” *Placenta*, vol. 24, no. 5, pp. 532–539, 2003.

[133] C. J. Petry, K. K. Ong, I. A. Hughes, C. L. Acerini, J. Frystyk, and D. B. Dunger, “Early pregnancy-associated plasma protein a concentrations are associated with third trimester insulin sensitivity,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 102, no. 6, pp. 2000–2008, 2017.

[134] F. Beneventi, M. Simonetta, E. Locatelli et al., “Temporal variation in soluble human leukocyte antigen-G (sHLA-G) and pregnancy-associated plasma protein A (PAPP-A) in pregnancies complicated by gestational diabetes mellitus and in controls,” *American Journal of Reproductive Immunology*, vol. 72, no. 4, pp. 413–421, 2014.

[135] L. Ozcan and I. Tabas, “Calcium signalling and ER stress in insulin resistance and atherosclerosis,” *Journal of Internal Medicine*, vol. 280, no. 5, pp. 457–464, 2016.

[136] E. B. Gür, O. Ince, G. A. Turan et al., “Ultrasonographic visceral fat thickness in the first trimester can predict metabolic syndrome and gestational diabetes mellitus,” *Endocrine*, vol. 47, no. 2, pp. 478–484, 2014.

[137] Z. Zhang, Q. Xu, Y. Chen et al., “The possible role of visceral fat in early pregnancy as a predictor of gestational diabetes mellitus by regulating adipose-derived exosomes miRNA-148 family: protocol for a nested case-control study in a cohort study,” *BMC Pregnancy and Childbirth*, vol. 21, no. 1, pp. 1–7, 2021.